Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab (SHR-1210) plus apatinib in advanced non-small cell lung cancer (phase II)
CTR20170090Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Jan 2017; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170090.